Leung Janice M, Tiew Pei Yee, Mac Aogáin Micheál, Budden Kurtis F, Yong Valerie Fei Lee, Thomas Sangeeta S, Pethe Kevin, Hansbro Philip M, Chotirmall Sanjay H
Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada.
Division of Respiratory Medicine, St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Respirology. 2017 May;22(4):634-650. doi: 10.1111/resp.13032. Epub 2017 Mar 25.
COPD is a major global concern, increasingly so in the context of ageing populations. The role of infections in disease pathogenesis and progression is known to be important, yet the mechanisms involved remain to be fully elucidated. While COPD pathogens such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae are strongly associated with acute exacerbations of COPD (AECOPD), the clinical relevance of these pathogens in stable COPD patients remains unclear. Immune responses in stable and colonized COPD patients are comparable to those detected in AECOPD, supporting a role for chronic colonization in COPD pathogenesis through perpetuation of deleterious immune responses. Advances in molecular diagnostics and metagenomics now allow the assessment of microbe-COPD interactions with unprecedented personalization and precision, revealing changes in microbiota associated with the COPD disease state. As microbial changes associated with AECOPD, disease severity and therapeutic intervention become apparent, a renewed focus has been placed on the microbiology of COPD and the characterization of the lung microbiome in both its acute and chronic states. Characterization of bacterial, viral and fungal microbiota as part of the lung microbiome has the potential to reveal previously unrecognized prognostic markers of COPD that predict disease outcome or infection susceptibility. Addressing such knowledge gaps will ultimately lead to a more complete understanding of the microbe-host interplay in COPD. This will permit clearer distinctions between acute and chronic infections and more granular patient stratification that will enable better management of these features and of COPD.
慢性阻塞性肺疾病(COPD)是一个重大的全球关注问题,在人口老龄化背景下愈发如此。已知感染在疾病发病机制和进展中发挥着重要作用,但其涉及的机制仍有待充分阐明。虽然诸如流感嗜血杆菌、卡他莫拉菌和肺炎链球菌等COPD病原体与COPD急性加重(AECOPD)密切相关,但这些病原体在稳定期COPD患者中的临床相关性仍不明确。稳定期和定植COPD患者的免疫反应与AECOPD中检测到的免疫反应相当,这支持了慢性定植通过有害免疫反应的持续存在在COPD发病机制中发挥作用。分子诊断和宏基因组学的进展现在使得以前所未有的个性化和精确性评估微生物与COPD的相互作用成为可能,揭示了与COPD疾病状态相关的微生物群变化。随着与AECOPD、疾病严重程度和治疗干预相关的微生物变化变得明显,人们重新将重点放在了COPD的微生物学以及急性和慢性状态下肺微生物群的特征描述上。将细菌、病毒和真菌微生物群作为肺微生物群的一部分进行特征描述,有可能揭示以前未被认识的COPD预后标志物,这些标志物可预测疾病结局或感染易感性。填补这些知识空白最终将有助于更全面地理解COPD中微生物与宿主的相互作用。这将使急性和慢性感染之间的区别更加清晰,患者分层更加细化,从而能够更好地管理这些特征以及COPD。